These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1709725)

  • 1. [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506].
    Hohlfeld R
    Nervenarzt; 1991 Feb; 62(2):136-8. PubMed ID: 1709725
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunosuppressive therapy].
    Schumacher K; Gross R
    Internist (Berl); 1984 Jan; 25(1):51-9. PubMed ID: 6370894
    [No Abstract]   [Full Text] [Related]  

  • 3. Transplantation's newest weapon FK 506.
    Pezze JL; Whiteman K
    Am J Nurs; 1991 Oct; 91(10):40-2. PubMed ID: 1716857
    [No Abstract]   [Full Text] [Related]  

  • 4. FK 506: an immunosuppressant for the 1990s?
    Macleod AM; Thomson AW
    Lancet; 1991 Jan; 337(8732):25-7. PubMed ID: 1702172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic trials for multiple sclerosis.
    McKhann GM
    Ann Neurol; 1990 Jun; 27(6):589-90. PubMed ID: 2193612
    [No Abstract]   [Full Text] [Related]  

  • 6. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.
    Siekierka JJ; Hung SH; Poe M; Lin CS; Sigal NH
    Nature; 1989 Oct; 341(6244):755-7. PubMed ID: 2477714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.
    Kay JE; Benzie CR; Goodier MR; Wick CJ; Doe SE
    Immunology; 1989 Aug; 67(4):473-7. PubMed ID: 2475433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunosuppressive therapy of multiple sclerosis using cyclosporin A and azathioprine. Long-term effects, risks, proton spin tomography and immunological findings].
    Kappos L
    Schriftenr Neurol; 1990; 32():1-200. PubMed ID: 2200108
    [No Abstract]   [Full Text] [Related]  

  • 9. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.
    Demetris AJ; Banner B; Fung J; Shapiro R; Jordan M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):944-6. PubMed ID: 1703360
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats.
    Thomson AW; Stephen ME; Woo J; Hasan NU; Whiting PH
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1048-9. PubMed ID: 2468203
    [No Abstract]   [Full Text] [Related]  

  • 11. Early infections in kidney transplant recipients under FK 506.
    Kusne S; Martin M; Shapiro R; Jordan M; Fung J; Alessiani M; Jain A; Todo S; Starzl T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):956-7. PubMed ID: 1703364
    [No Abstract]   [Full Text] [Related]  

  • 12. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent.
    Staschak S; Wagner S; Block G; Van Thiel DH; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):47-9. PubMed ID: 1689896
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter.
    Baumann G; Geisse S; Sullivan M
    New Biol; 1991 Mar; 3(3):270-8. PubMed ID: 1715185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of T and B lymphocyte proliferation by rapamycin.
    Kay JE; Kromwel L; Doe SE; Denyer M
    Immunology; 1991 Apr; 72(4):544-9. PubMed ID: 1709916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506.
    Sunyecz JA; Price FV; Trucco G; Thomas R; Swerdlow SH
    Gynecol Oncol; 1996 Aug; 62(2):301-3. PubMed ID: 8751565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic problems in disseminated encephalomyelitis (multiple sclerosis)].
    Payk TR
    Ther Ggw; 1973 Mar; 112(3):349-50. PubMed ID: 4573496
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular immunity in multiple sclerosis. Implications for pathogenesis and treatment.
    Thompson RF; Davenport J
    Mo Med; 1984 Oct; 81(10):669-73. PubMed ID: 6092887
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis].
    Schluep M; Steck AJ; Despland PA; Regli F; Ochsner F; Berrut E; Gauthier G
    Schweiz Rundsch Med Prax; 1991 Jun; 80(24):670-2. PubMed ID: 2068440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.
    Flanagan WM; Corthésy B; Bram RJ; Crabtree GR
    Nature; 1991 Aug; 352(6338):803-7. PubMed ID: 1715516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.
    Walliser P; Benzie CR; Kay JE
    Immunology; 1989 Nov; 68(3):434-5. PubMed ID: 2480331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.